Lu-AAZTA-NI-PSMA-093

Lu-AAZTA-NI-PSMA-093

• UNSPSC Description: Lu-AAZTA-NI-PSMA-093 is a bivalent radiopharmaceutical agent for prostate cancer, that enhances tumor uptake and retention by combining a hypoxia-sensitive nitroimidazole (NI) moiety with a targeting moiety to PSMA[1].
• Target Antigen: Others
• Type: Reference compound
• Related Pathways: Others
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/lu-aazta-ni-psma-093.html
• Smiles: O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC([C@@H](NC(COC1=CC=C(C[C@H](NC(CNC(CC[C@H](NC(CCCCC2(N(CC(O3)=O)CC(O4)=O)C[N@]5(CC(O[Lu]6435OC(C7)=O)=O)CC[N@]67C2)=O)C(NCCCN8C=CN=C8[N+]([O-])=O)=O)=O)=O)C(O)=O)C=C1)=O)CC9=CC=CC=C9)=O)=O
• Molecular Weight: 1626.37
• References & Citations: [1]Luo Y, et al., 68Ga/177Lu-Labeled Bivalent Agents for Targeting Hypoxia and PSMA-Binding in Prostate Cancer. J Med Chem. 2024 Aug 8;67(15):13491-13506.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported